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The objective was an assessment of the impact of 
Leonurus cardiaca L. extract (LCE) and ursolic acid (UA) 
on the adhesive properties of Staphylococus aureus NCTC 
8325 strain, expressing virulence factors important in the 
pathogenesis of infective endocarditis. The adhesion and 
biofilm formation of bacteria cultured in the presence of 
subinhibitory concentrations of LCE or UA on the abiotic 
surface or covered with fibrinogen, fibronectin or colla-
gen, were evaluated. Inhibitory effects of LCE and UA on 
staphylococcal adherence to both types of surface were 
demonstrated. This, in the case of UA, resulted in a sig-
nificant reduction of biofilm formation.
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INTRODUCTION
Infective endocarditis (IE) is often a fatal disease, which 
mostly develops as a complication of heart surgery or 
anatomical disorders, mainly in the valves. Occasionally, 
but in last few years with significantly growing frequency, 
it may occur in individuals without clear risk factors. The 
native valve staphylococcal IE is usually caused by Staphy- 
lococcus aureus. In contrast, the prosthetic valve infection 
is more often caused by a coagulase-negative staphylo-
cocci (S. epidermidis). Both bacteria species possess nu-
merous surface-bound and extracellular proteins recog-
nizing extracellular matrix components (ECM), which are 
exposed on the inflamed heart tissue. The resulting “veg-
etations” are composed of the bacterial cells forming 
biofilm, fibrin, platelet clots, leukocytes and erythrocytes. 
It has been found that plasma-derived protein “bridges”, 
between staphylococcal receptors and thrombocytes, are 
formed from fibrinogen, fibrin, thrombospondin and 
von Willebrand factor (Hauck & Ohlsen, 2006). Staph-
ylococci bind also avidly to endothelial cells through 
adhesin-receptor interactions (SpA, von Willebrand-fac-
tor binding protein, FbpA and ClfA, ClfB). Two other 
S. aureus products (secretable) interact with hemostasis 
system, but at two different stages. Coagulase- prothrom-
bin binding results in the formation of active ‘’staphylo-
thrombin’’ and fibrin generation, whereas staphylokinase, 
which binds plasminogen and facilitates plasmin activity 
is a thrombolytic agent. On the other hand, targets of 
α-toxin include lymphocytes, macrophages, epithelium, 
endothelium, and erythrocytes. This toxin has also been 
proposed to play a role in biofilm formation by increas-
ing the bacterial cell-to-cell interactions (Anderson et al., 
2012; McAdow et al., 2012; Zhang et al., 2011).
Because of the risk of serious sequelae, patients with 
IE undergo compulsory treatment with antibiotics, un-
fortunately, due to the drug-resistance and the tendency 
of bacteria to grow in a biofilm, such treatment is often 
ineffective (Widmer et al., 2006). Since the most com-
mon cause of death of IE patients is an appearance of 
clots derived from vegetations, they are routinely admin-
istered antiplatelet/anticoagulation drugs. Taking into ac-
count that resistance to some of these drugs is also an 
emerging clinical entity, it would be interesting to deter-
mine similar properties of naturally occurring substances 
(e.g. plant extracts or their components), which in future 
could be used as the alternatives to the currently known 
chemotherapeutics (Fraga et al., 2010). The results of our 
unpublished preliminary studies on the biological activity 
of several plant extracts rich in polyphenols drew atten-
tion to the Leonurus cardiaca herb extract and one of its 
compounds — an ursolic acid. Both products demon-
strated interesting antimicrobial, antiplatelet and immu-
nomodulatory activities. Another reason for an interest 
in L. cardiaca herb extract is its known beneficial effect 
on heart and cardiocirculatory system. It is a part of the 
preparations, such as Cardiosan, Cardionervit, Cardiogran 
and many others used, for example, to strengthen the 
heart muscle, possessing biological features which are 
compared in many respects with those derived from Va-
lerianae radix and Melissae folium (Wojtyniak et al., 2013). 
However, due to the simultaneous antimicrobial activity 
of L. cardiaca extract / ursolic acid, the main objective 
of the present study is an assessment of their impact on 
the expression of S. aureus attributes, taking part in the 
initial steps of pathogenesis of infective endocarditis. The 
study includes evaluation of: i) adhesion of pathogens 
to an inert plastic surface or to a surface covered with 
ECM components (fibrinogen, fibronectin, collagen), 
resembling for example a heart valve prosthesis, ii) bio-
film formation in the above circumstances, reproducing 
roughly the bacterial behavior involved in the formation 
of vegetations.
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MATERIALS AND METHODS
Bacterial strains to be tested. The study was per-
formed on a model Staphylococcus aureus 8325-4 (NCTC 
8325) strain expressing virulence factors of the 
MSCRAMMs/SERAMMs group — α-toxin+, SpA+, 
Coa+, ClfA+ ClfB-, SAK+. Their expression was earlier 
proved in our Lab. Briefly, SpA (staphylococcal protein 
A) was detected using goat anti-SpA FITC-labeled IgG; 
SAK (staphylokinase) was detected on the basis of the 
reduction of the chromogenic substrate; α-hemolysin 
secretion was evaluated as an intensity of hemolysis of 
the sheep red blood cells and with the Western blot 
using anti-α-tox mAb; expression of a fibrinogen re-
ceptor (ClfA, clumping factor A) was assessed using a 
semi-quantitative Latex S. aureus test; coagulase (Coa) 
production was evaluated in the rabbit plasma coagula-
tion test (Sadowska, 2010).
Preparation and chemical characterization of the 
Leonurus cardiaca extract (LCE). Motherwort (Leonurus 
cardiaca L.) was a commercial sample supplied by 
KAWON-HURT Nowak sp.j. (Gostyń, Poland). Leaves 
were extracted with acetone-water (70:30, v/v) at a solid 
to liquid ratio 1:10 (w/v), at room temperature for 30 
min and then centrifuged for 15 min (4000 rpm). The 
pellets were re-extracted twice with 70% aqueous ace-
tone for 15 min and the supernatants were combined. 
After the removal of acetone with a vacuum rotary evap-
orator (Rotavapor RII, Büchi, Switzerland) at <40°C, 
the extracts were subjected to liquid-liquid partition with 
chloroform (1:1 v/v) nine times. The water fractions 
were concentrated in vacuum, and lyophilized (Alpha 
1–2 LD plus, Christ) with the yield of 14.47%. Dried 
extracts were reconstituted at 5 mg/ml of water before 
analysis. Qualitative and quantitative composition of 
LCE was determined using spectrophotometric methods 
and HPLC-PDA analysis. On the basis of spectral iden-
tification and maximum of UV-Vis absorption, phenolics 
were qualified in four subclasses: flavanols and hydroxy-
benzoic acids (expressed as gallic acid equivalents; detec-
tion at 280 nm), hydroxycinnamic acids (as chlorogenic 
acid equivalents; detection at 320 nm), flavonols (as rutin 
equivalents; detection at 360 nm), and anthocyanins (as 
cyanidin 3-glucoside equivalents; detection at 520 nm). 
The results were expressed as mg/g of extract.
 Ursolic acid (UA) ≥ 90% purity was purchased from 
Sigma, USA.
Antimicrobial activity of LCE and UA. MIC (min-
imal inhibitory concentration) values were specified by 
a standard microdilution broth assay. Stock solution of 
LCE was prepared in 50% DMSO, while UA in 96.0% 
EtOH (PoCh, Poland). The concentration ranges of the 
compounds (in the two-fold dilutions system in 96-well 
microplates) were of: 0.0625–2.0 mg/ml (UA) and 0.5–
6.0 mg/ml (LCE). Subsequently, the bacterial suspension 
(100 μl) was added (1:1) to the wells. Phytocompounds 
dilutions without bacteria were prepared as the negative 
control, while for a positive control bacterial suspensions 
in Mueller-Hinton broth were added to the wells. The fi-
nal highest DMSO concentration was 1.25% and EtOH 
was 4.25%, which did not affect bacterial growth. Plates 
were incubated at 37°C for 18 h and the lowest con-
centration showing no turbidity was recorded as MIC. In 
each case, experiments were carried out in quadruplicate 
in two separate occasions.
Anti-adhesive and anti-biofilm properties of LCE 
and UA. The suspension of S. aureus strain (1–5 × 107 
CFU/ml) was prepared in adhesion/biofilm promoting 
medium — tryptic soya broth (TSB) supplemented with 
0.25% glucose (TSB/Glu). The experiment scheme was 
as follows: (A) — 96-well microplates with immobi-
lized fibrinogen 2 µg/well (Sigma, USA), collagen I, rat 
tail (Life Technologies, USA) or fibronectin, 1 µg/well 
(R&D Systems, Inc.) were used; (B) 96-well polystyrene 
microplates (Nunc, Roskilde, Denmark) with uncoated 
wells were used. In all cases 100 µl of S. aureus sus-
pension and 100 µl of LCE or UA at final ½ or ¾ 
MIC were added and incubated for 2 h at 37°C; (C) 
anti-biofilm activity of LCE and UA was tested when 
the above described experiments (A) and (B) were pro-
longed to 24 h. In this case only ¾ MIC of LCE and 
UA was used. Negative controls in each experiment 
version (A, B, C) were wells containing only dilutions 
of phytocompounds in DMSO (½ or ¾ MIC), while 
positive controls were wells containing bacterial sus-
pensions and TSB/Glu. To evaluate adhesion/biofilm 
formation of bacteria, Alamar Blue (AB, Trek Diag-
nostic Systems, Inc. USA) staining protocol was used 
as recommended by the manufacturer. Briefly, 5 µl of 
Alamar Blue (AB, BioSource, USA) was added to the 
wells of 96-well tissue culture polystyrene plate (Nun-
clon Surface, Nunc, Denmark), containing bacterial cul-
tures after an appropriate time of their exposition on 
phytochemicals or medium (control). Then, the plates 
were incubated for 1 h at 37°C (with shaking). Finally, 
the absorbance was determined at 550 nm and 600 nm 
using a multifunctional counter (Victor2, Wallac, Fin-
land). The percentage of AB reduction was calculated 
according to the manufacturer formula. Relative chang-
es in bacterial adhesion were expressed as a percentage 
of attached cells incubated in the presence of subMIC 
of phytocompounds ± S.D., compared to the positive 
control. In each case, experiments were carried out in 
quadruplicate in two separate occasions.
Statistic analysis of data. Differences in parameters 
were tested for significance using the Mann-Whitney U 
test and the program Statistica 10.0 (Stat Soft Inc.). The 
differences with P<0.05 were considered to be statisti-
cally significant.
RESULTS AND DISCUSSION
The phytochemical analysis showed that the total con-
tent of polyphenols in L. cardiaca L. extract (LCE), ex-
pressed as a gallic acid equivalent averaged from three 
measurements, was 115.12±11.5 mg/g. The HPLC 
analysis demonstrated their amount as 182.75±14.57 
mg/g. Hydroxycinnamic acids (caffeic acid, ferulic acid 
and p-coumaric acid) content calculated as chlorogenic 
acids was 172.01±14.34 mg/g. The minimal inhibito-
ry concentration (MIC) of this extract against S. aureus 
8325-4 (NCTC 8325) was 6 mg/ml, whereas MIC of ur-
solic acid (UA) was 0.25 mg/ml. In subsequent experi-
ments dedicated to the assessment of adhesion/biofilm 
formation, ½ and ¾ MIC of these products were used. 
Why were the subinhibitory concentrations exmined? 
Because it is known that the beneficial effect of antibi-
otic or other drug is not only achieved when the con-
centration is above the minimal inhibitory concentration 
(MIC) between consecutive doses. It has been shown in 
vitro that, depending on the pharmacokinetic and phar-
macodynamic properties, the subMIC of a given product 
is able to affect important bacterial characteristics (Sad-
owska, 2010). Due to the specific pathogenesis course of 
infective endocarditis, it can be assumed that achieving the 
MIC concentration of a product at the inflammation site 
is unlikely. Moreover, the products tested by us possess 
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(at MIC) unfavorable biocompatibility index, which ex-
cludes their use at a higher concentration (not shown).
The microplate Alamar Blue assay (MABA) used in 
the study showed the inhibitory effects of LCE and UA 
on staphylococcal adherence to an inert surface. The 
percentage of the inhibition of adherence to uncoated 
wells of polystyrene plates ranged from 14.2% to 72.4%, 
dependent on the type (LCE, UA) and concentration of 
each phytocompound (½ or ¾ MIC). This limitation of 
bacterial settlement was not caused by the decrease in 
their viability per se, since the growth rate of S. aureus sus-
pension culture (tested in parallel after 2 h co-incubation 
by MABA) was not affected. The specific adherence of 
bacteria to the microplate wells containing immobilized 
extracellular matrix proteins (ECM) was also diminished. 
For example, ursolic acid (UA) used in a concentration 
of ¾ MIC limited bacterial adhesion to collagen-coated 
wells by 73.2%, to fibronectin-coated wells by 58.8%, 
and to fibrinogen-coated surface by 65.9%. The L. car-
diaca extract used at ¾ MIC showed the activity twice 
as weak as ursolic acid (in the range of 23.2–32.4%), 
significant only in the case of a collagen coated surface. 
When LCE and UA were used at a lower concentration 
(½ MIC), the obtained inhibitory effect was weaker. The 
data in Fig. 1A represents the results obtained in experi-
ments where ¾ MICs of the compounds were used.
The exposure of ECM neoepitopes, deposition of 
platelets and fibrin at the site of inflammation, as well 
as the expression of the various molecules on capillary 
endothelial cells, occur in the heart area. These condi-
tions lead to a local inflammatory process and coagula-
tion, and created a perfect surface for the attachment of 
a pathogen (Chavakis et al., 2005; Edwards & Massey, 
2011; McAdow et al., 2011; Kim et al., 2012). Therefore, 
a limitation of the adhesion by the L. cardiaca extract 
and ursolic acid indicate a new potential application of 
these compounds. In another study, conducted by us at 
the same time in a different direction than the one pre-
sented here, it was found that both phytocompounds (at 
concentrations of 0.5 to 50 μg/ml) inhibit the adhesion 
of platelets to immobilized collagen. Moreover, these 
products, when co-incubated with human plasma, inhibit 
(in a dose dependent manner) fibrinogen polymerization 
(data not yet published). Thus, the L. cardiaca extract as 
well as ursolic acid, in addition to the very interesting 
anti-staphylococcal activity detected in the present study, 
not only modulate platelet functions but may also change 
properties of fibrinogen, which is a key protein in blood 
coagulation.
Thus, the weakened S. aureus adherence caused by the 
presence of LCE and UA in the culture medium is a 
beneficial effect, especially because it resulted in the sta-
tistically significant reduction in the metabolic potency of 
bacterial mass (biofilm) formed during subsequent 24 h 
incubation (Fig. 1B). If we relate these observations to 
the real situation in vivo, we may suppose and anticipate 
that vegetations would be smaller/weaker and less prone 
to detachment, if such a type of products is present in 
Figure 1. Anti-adherent and anti-biofilm activity of Leonurus cardiaca-derived extract and ursolic acid against S. aureus NCTC 8325. 
Bacteria were cultured for 2 or 24 h on microplates without or with immobilized fibrinogen, fibronectin or collagen, in absence or con-
stant presence of the phytocompounds used at their ¾ MIC. Adhesion (A) and biofilm formation (B) were evaluated by staining with 
Alamar Blue. Results are presented as the percentage of the biomass viability, compared to the control, accepted as 100%. All presented 
results are mean from 2 independent experiments performed in quadruplicate ± S.D. *p<0.05
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a given microenvironment. The comparison of the de-
gree of the Alamar Blue reduction by cells in biofilm, 
which developed in the presence of phytochemicals, 
showed a decrease in their formation. LCE was a weak 
inhibitor, since it caused only 5% inhibition of biofilm 
formation on the inert polystyrene surface and approxi-
mately 1-10% reduction on an surface coated with ECM 
proteins, whereas ursolic acid proved to be very effec-
tive. At a concentration of ¾ MIC UA limited biofilm 
formation on the surface, both on inert (by 85%) and 
on coated with ECM proteins (approximately 70-86%). 
Although the exact mechanism by which the tested phy-
tocompounds affects S. aureus cells during the adhesion 
and biofilm development is at the moment unknown, it 
can be assumed that it is based on modification of the 
surface adhesins molecular architecture, their expression 
and/or influence on the cell-surface hydrophobicity. This 
remains to be determined in further studies just under-
taken in the our Lab. The original plant extract used in 
the study — L. cardiaca is known as a herb used in tra-
ditional medicine, being applied in the cases for a va-
riety of illnesses. It contains alkaloid leonurine, which 
is a mild vasodilator, and therefore, has long been used 
as a sedative in heart neurosis. Among other biochemi-
cal constituents, it also contains bitter iridoid glycosides, 
di- and triterpenoids, flavonoids, tannins and volatile oils 
(Wojtyniak et al., 2013). The L. cardiaca extract tested in 
the present study was characterized as presented above 
and was shown to contain high amounts of known bio-
logically active components. Another product tested in 
this study — ursolic acid, belongs to the main group 
of triterpenoids represented by pentacyclic derivatives, 
which are ubiquitous in the plant kingdom, including 
L. cardiaca. Several biochemical and pharmacological 
effects of UA such as anti-inflammatory, antioxidant, 
anti-proliferative, anti-cancer, anti-mutagenic, anti-ather-
osclerotic, anti-hypertensive, anti-leukemic and antiviral 
properties are reported in a number of experimental sys-
tems (Checker & Sainis, 2012). Through the presented 
results we provide additional valuable information on the 
biological properties of these phytochemicals, which had 
not been tested before in the range covered by our re-
search.
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